Lenzetto

Estradiol, the active ingredient in Lenzetto, is an estrogen presented as a transdermal patch for transdermal use. It treats menopausal symptoms, estrogen deficiency and hypoestrogenism in women. GNH USA supplies Lenzetto as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lenzetto provides estrogen replacement through the transdermal route, addressing conditions related to low endogenous estrogen. - Menopausal symptoms: reduces hot flashes, night sweats and improves mood. - Estrogen deficiency: restores systemic estrogen levels and alleviates associated vasomotor disturbances. - Hypoestrogenism: supports bone health and urogenital tissue integrity in women with low estrogen production.

Common Side Effects: - Skin irritation at the application site: redness or itching where the patch is applied. - Headache: mild to moderate intensity. - Nausea: occasional upset stomach. - Breast tenderness: mild discomfort or swelling. - Mood changes: fluctuations in emotional state. - Fluid retention: mild swelling of ankles or feet.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Stroke: cerebrovascular accident risk. - Myocardial infarction: heart attack. - Hepatotoxicity: liver enzyme elevation. - Endometrial hyperplasia: abnormal uterine lining growth. - Gallbladder disease: biliary colic or cholecystitis.

Before initiating therapy, consider patient‑specific risk factors and monitor appropriately. - Assess cardiovascular risk: evaluate history of clotting disorders or thrombosis. - Monitor breast changes: report any new lumps or discharge. - Consider bone health: assess osteoporosis risk in long‑term use. - Avoid use in active liver disease: contraindicated in severe hepatic impairment. - Pregnancy and lactation: not recommended due to unknown safety. - Store at room temperature: keep in the original pouch, protect from light and moisture.

Estradiol may interact with several drug classes, requiring careful management. Major Interactions (Avoid): - Combined estrogen therapy (e.g., oral contraceptives): increased thrombotic risk. - Tamoxifen: antagonistic effect reducing therapeutic benefit. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower estradiol levels. - Azole antifungals (e.g., ketoconazole): can raise estradiol concentrations. - Anticoagulants (e.g., warfarin): may enhance anticoagulant effect. Moderate Interactions (Monitor Closely): - SSRIs (especially fluoxetine, paroxetine): may diminish hot‑flash relief. - Antihypertensives: monitor blood pressure for potential changes. - Thyroid hormone replacement: assess thyroid function periodically. - Antidiabetic agents: observe glucose control as estrogen can affect insulin sensitivity.